Macquarie Group’s XBiotech XBIT Stock Holding History

Macquarie Group’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-576	Closed	-$5	–	2162
2024 Q1	$5	Buy	+576	New	+$3.3K	﹤0.01%	1800

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Macquarie Group's XBIT Position: Q2 2024 in Review

Macquarie Group sold out of XBiotech (XBIT) in Q2 2024, closing a stake of 576 shares — an estimated $5 sold.

Macquarie Group first reported a position in XBIT in Q1 2024 and held it in 1 quarter. The position peaked at $5 in Q1 2024. 46 funds tracked by Wall St. Rank hold XBIT as of Q2 2024.

Macquarie Group reported no remaining XBiotech position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 576 XBiotech shares in Q2 2024, an estimated $5.
Macquarie Group first reported a position in XBiotech in Q1 2024 and held it in 1 quarter.
Macquarie Group's XBiotech position peaked at $5 in Q1 2024.
46 funds tracked by Wall St. Rank held XBiotech as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.